3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Paclitaxel
47
Carboplatin
38
liposomal doxorubicin
25
Bevacizumab
23
Gemcitabine
18
Topotecan
15
pembrolizumab
14
mirvetuximab soravtansine
11
rucaparib
8
niraparib
7
Cisplatin
7
1-dodecylpyridoxal
7
trebananib
6
Drug Therapy
6
130-nm albumin-bound paclitaxel
6
Nivolumab
5
Cyclophosphamide
5
cemiplimab
4
sarilumab
3
relacorilant
3
pazopanib
3
oregovomab
3
olaparib
3
Doxorubicin
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
tocilizumab
2
seribantumab
2
phenoxodiol
2
pegfilgrastim
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Fallopian Tube Neoplasms
×
Histamine Antagonists
×
Clear all
NCT06824467
2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled